Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting

2023-506308-24-00 Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD… Recruiting

2023-506888-34-00 Advanced or metastatic solid tumors including hormone r 1 2024-05-22
A study of ASP3082 in adults with advanced solid tumors Recruiting

2022-501590-39-00 Solid Tumor 1 2024-05-22
A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercapto… Recruiting

2022-501992-15-00 Acute Myeloid Leukemia (AML) 9 2024-05-21
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye… Recruiting

2023-507677-18-00 Chronic Myeloid Leukemia 9 2024-05-17
Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, th… Recruiting

2023-509204-15-00 Metastatic colorectal cancer 4 2024-05-17
Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c… Recruiting

2023-505024-62-01 Oligometastatic patients with castration-resistant pro 4 2024-05-16
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 multiple myeloma 5 2024-05-14
Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Recruiting

2024-513601-31-00 Acute lymphoid leukemia 4 2024-05-13
First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma Recruiting

2023-507213-97-00 Relapsed/refractory B-cell aggressive lymphoma 1 2024-05-09
Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting

2024-511397-70-00 metastatic renal cell carcinoma (mRCC) 4 2024-05-06
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies Recruiting

2022-501648-14-00 Relapsed or refractory CD19 positive B cell malignancie 9 2024-05-05
A Phase I/IIa multicenter study evaluating the safety and efficacy of CAR20(NAP)-T in patients with relapsed/refractory B cell lymphoma (CAR… Recruiting

2024-511844-18-00 Relapsed or refractory CD20+ diffuse large B-cell lymph 7 2024-05-02
Basket study for oligo-metastatic breast cancer - ANISE Recruiting

2023-505039-11-00 breast cancer, HER2-positive, oligometastatic disease 4 2024-05-02
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom… Recruiting

2023-507632-20-00 Multiple Myeloma 5 2024-05-01
Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (PM-CARE). Single arm… Recruiting

2024-516498-57-00 liver predominant intrahepatic cholangiocarcinoma 4 2024-04-30
Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study Recruiting

2024-511886-12-00 Unfavorable intermediate/high risk prostate cancer pati 4 2024-04-29
A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip… Recruiting

2023-507305-33-00 Patients with ER+ HER2- advanced breast cancer and pati 7 2024-04-29
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch… Recruiting

2023-505660-11-00 Cholangiocarcinoma (LTT, 26.0) 5 2024-04-24
Examining the impact of propranolol on preoperative anxiety and on tumorigenic changes in patients with pancreatic ductal adenocarcinomas: a… Recruiting

2023-506553-37-00 Pancreatic ductal adenocarcinoma (PDAC) 4 2024-04-23
Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting

2023-504044-34-00 Untreated Chronic Lymphocytic Leukemia 4 2024-04-17
A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people… Recruiting

2022-502576-23-00 Platinum-resistant recurrent (PRR) ovarian cancer, Plat 1 2024-04-17
Study to compare the activation of the immune system depending on the chemotherapy scheme used together with PEMBROLIZUM (immunotherapy) in … Recruiting

2023-507008-30-00 High risk (TILs-positive) HR-/HER2- (triple negative) b 4 2024-04-17
CardioPROTECTion With Dapagliflozin in Breast Cancer Patients Treated With AnthrAcycline - PROTECTAA TRIAL Recruiting

2023-506631-15-00 Patients with invasive breast cancer, on stage I-III, a 5 2024-04-15